The mesenchymal stem cell’s superpower: Hacking the TME

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

Prostate cancer: HCPs discuss emerging treatments, artificia...

In March, the UK marked Prostate Cancer Awareness Month - a period dedicated to boosting recognition and tackling stigma of a cancer that affects approximately one in eight men nationwide.<

The complement system: The driving force behind a new genera...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease.

Quantro Therapeutics and the future of drug discovery: Insig...

A quarter of cancer patients don’t respond to targeted thera...

The more progress we make in precision medicine, the more edge cases we discover.

Patient-focused manufacturing models for personalised therap...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.